Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks  by John, Stefan et al.
Rapid Improvement of Nitric Oxide
Bioavailability After Lipid-Lowering
Therapy With Cerivastatin Within Two Weeks
Stefan John, MD, Christian Delles, MD, Johannes Jacobi, MD, Markus P. Schlaich, MD,
Markus Schneider, MD, Gerd Schmitz, MD, Roland E. Schmieder, MD, FACC
Erlangen-Nu¨rnberg and Regensburg, Germany
OBJECTIVES We investigated whether improvement of endothelial dysfunction in hypercholesterolemia
can be achieved with short-term lipid-lowering therapy.
BACKGROUND Impaired endothelium-dependent vasodilation plays a pivotal role in the pathogenesis of
atherosclerosis and acute coronary syndromes.
METHODS In a randomized, double-blind, placebo-controlled trial, we studied 37 patients (52 6 11 yrs)
with low density lipoprotein cholesterol $160 mg/dl (196 6 44 mg/dl) randomly assigned to
either cerivastatin (0.4 mg/d) or placebo. Endothelium-dependent vasodilation of the forearm
vasculature was measured by plethysmography and intra-arterial infusion of acetylcholine
(ACh 12, 48 mg/min) and endothelium-independent vasodilation by intra-arterial infusion of
nitroprusside (3.2, 12.8 mg/min).
RESULTS Low density lipoprotein cholesterol decreased after two weeks of treatment (cerivastatin 233 6
4% vs. placebo 1 2 6 4%, x 6 SEM, p , 0.001). Endothelium-dependent vasodilation improved
after two weeks of therapy with cerivastatin compared with baseline (ACh 12 mg/min: 1 22.3 6
5.2 vs. 1 11.2 6 1.9 ml/min/100 ml, p , 0.01; ACh 48 mg/min: 131.2 6 6.3 vs. 119.1 6 3.1
ml/min/100 ml, p , 0.05). In contrast, changes in forearm blood flow to ACh were similar before
and after therapy in the placebo group (ACh 12 mg/min: 112.9 6 3.6 vs. 19.0 6 1.9 ml/min/100
ml, NS; ACh 48 mg/min: 120.7 6 3.7 vs. 19.4 6 2.9 ml/min/100 ml, NS). Endothelium-
dependent vasodilation improved in comparison with placebo (ACh 48 mg/min: 1203 6 85%
[cerivastatin] vs. 226 6 71% [placebo], p , 0.05). This improvement in endothelium-dependent
vasodilation was no longer observed when the nitric oxide-synthase inhibitor N(G)-monomethyl-
L-arginine was coinfused (ACh 48 mg/min 1 N(G)-monomethyl-L-arginine 4 mmol/min
248 6 85% [cerivastatin]).
CONCLUSIONS Short-term lipid-lowering therapy with cerivastatin can improve endothelial function and
NO bioavailability after two weeks in patients with hypercholesterolemia. (J Am Coll
Cardiol 2001;37:1351–8) © 2001 by the American College of Cardiology
Recent studies have shown that cholesterol-lowering therapy
improves endothelium-dependent vasodilation in coronary
(1,2) and systemic (3) arteries due to an increased bioavailabil-
ity of nitric oxide (NO) (4), the most important endothelium-
derived vasodilating substance. Apart from vasodilating effects,
NO has been found to be a principal factor involved in the
antiatherosclerotic properties of the endothelium (5). Nitric
oxide interferes with key events in the development of
atherosclerotic plaques, such as monocyte and leukocyte
adhesion to the endothelium (6,7) and platelet aggregation and
adhesion (8). Endothelial expression of adhesion molecules
and proinflammatory cytokines involved in active inflamma-
tion and accumulation of macrophages at sites of plaque
rupture is selectively reduced by NO (6,9). Nitric oxide also
decreases endothelial permeability (9), and inhibits vascular
smooth muscle cell proliferation (10). In accordance with these
findings, inhibition of the NO-producing enzyme, NO syn-
thase causes accelerated atherosclerosis in experimental
models (11). Thus, improvement of the bioavailability of NO
seems to play a pivotal role in the regression and delayed
progression of coronary atherosclerosis induced by lipid-
lowering therapy (12).
Increased bioavailability of NO has been demonstrated after
six months of lipid-lowering therapy (4). Improvement of
endothelial function can occur after four (13) to six (14) weeks
of oral pharmacologic therapy with different HMG-CoA
reductase inhibitors. In addition, improved endothelial func-
tion has been observed even after a single low density lipopro-
tein (LDL) apheresis within hours (15,16). Rapid improve-
ment of NO bioavailability is most attractive, since it offers an
early and new therapeutic approach in acute coronary syn-
dromes. Nevertheless, lipid-lowering therapy is often delayed
after acute coronary syndromes because of the usual practice of
initially starting cholesterol lowering with dietary therapy (17).
The objective of this study was to determine whether lipid-
lowering therapy with a statin can rapidly improve endothelial
function via improved bioavailability of NO in the forearm
vasculature in patients with hypercholesterolemia.
METHODS
Study population. In a randomized, placebo-controlled,
double-blind study, patients were randomly assigned to
either placebo or cerivastatin for a period of 14 days.
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Inclusion criteria were: age 20 to 65 years, increased serum
LDL cholesterol level of $160 mg/dl and serum triglyceride
level #400 mg/dl while not receiving cholesterol-lowering
medication. Exclusion criteria were: patients with active
smoking habits and nonsmokers with ,1 year of cessation,
diabetes mellitus (HbA1c . 7% or fasting blood glucose .
120 mg/dl or antidiabetic medication), arterial hypertension
(diastolic blood pressure $ 95 mm Hg or systolic blood
pressure $ 160 mm Hg) or presently taking any blood
pressure-lowering agent, any cardiovascular or cerebrovas-
cular event within the last three months, overt peripheral
vascular disease, severe cardiac pathologies (uncontrolled
arrythmias, atrial fibrillation, unstable angina, congestive
heart failure, New York Heart Association classification
II–IV, coronary artery bypass grafting or percutaneous
transluminal coronary angioplasty within the previous six
months), known intolerance or hypersensitivity to statins,
severe disorders of the gastrointestinal tract (chronic diar-
rhea, ulcerative colitis, etc.), pregnant or lactating women,
familial monogenic hypercholesterolemia, secondary hyper-
lipoproteinemia, vascular abnormalities in the forearm vas-
culature, liver or kidney disease (AST and ALT levels .
200% of upper normal limit, alkaline phosphatase, bilirubin
and serum creatinine . 150% of upper normal limit),
patients regularly or occasionally practicing weightlifting or
body building, patients who work on night shifts, patients
who are taking any lipid-lowering medication or patients on
steroids or immunosuppressive agents.
Thirty-seven patients were included in this randomized,
double-blind, placebo-controlled trial. They were randomly
assigned by a randomization list in a 1:1 fashion to the
treatment (n 5 19) or the placebo group (n 5 18). One
patient in the cerivastatin group did not complete the study
(withdrawal of consent). Another patient in the treatment
group took the medication for 20 days instead of 14 days
and was, therefore, excluded from per protocol analysis.
Thus, 17 patients in the cerivastatin group and 18 patients
in the placebo group entered statistical analysis. The base-
line characteristics of these patients were not different
between the treatment and placebo group, except for dif-
ferences in body weight (Table 1). In addition to the
abovementioned study population, 19 healthy subjects (age
51 6 6 years), all nonsmokers with normal total cholesterol
levels (189 6 31 mg/dl), LDL cholesterol levels (95 6
24 mg/dl), blood pressure and fasting blood glucose, were
Table 1. Baseline Characteristics and Lipid Profiles of Patients With Hypercholesterolemia







Gender (m/f) 9/8 13/5 NS
Age (yrs) 51.3 6 11 52.7 6 10 NS
Height (m) 1.69 6 0.09 1.74 6 0.08 NS
Weight (kg) 72 6 12 78 6 10 0.025
Body mass index (kg/m2) 24.5 6 2.2 25.7 6 2.3 NS
Blood pressure
Systolic (mm Hg) 127 6 12 132 6 10 NS
Diastolic (mm Hg) 81 6 8 83 6 5 NS
Active smoker (yes/no) 0/17 0/18 NS
Hypertensives (yes/no) 0/17 0/18 NS
Total cholesterol (mg/dl) 286 6 54 283 6 46 NS
HDL cholesterol (mg/dl) 51 6 16 54 6 11 NS
LDL cholesterol (mg/dl) 198 6 45 196 6 42 NS
LDL/HDL ratio 4.2 6 2.0 3.8 6 1.1 NS
Triglycerides (mg/dl) 174 6 103 167 6 68 NS
VLDL (mg/dl) 46 6 51 37 6 25 NS
Fibrinogen (mg/dl) 317 6 17 299 6 16 NS
Apolipoprotein B (mg/dl) 143 6 30 139 6 23 NS
Apolipoprotein E (mg/dl) 5.1 6 1.6 3.9 6 1.0 NS
Lipoprotein (a) (mg/dl) 39 6 45 20 6 26 NS
Homocysteine (mmol/l) 9.5 6 2.6 11.7 6 4.8 NS
t-PA (mg/ml) 7.9 6 3.7 8.9 6 4.6 NS
PAI-1 (U/ml) 3.7 6 2.1 3.7 6 1.9 NS
von Willebrand factor-antigen (%) 170 6 80 163 6 88 NS
Thrombomodulin (ng/ml) 3.5 6 1.4 3.5 6 1.1 NS
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; PAI-1 5 plasminogen activator inhibitor type 1; t-PA 5
tissue-type plasminogen activator; VLDL 5 very low density lipoprotein.
Abbreviations and Acronyms
ACh 5 acetylcholine
ANOVA 5 analysis of variance
FBF 5 forearm blood flow
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
L-NMMA 5 N(G)-monomethyl-L-arginine
NO 5 nitric oxide
PAI-1 5 plasminogen activator inhibitor type 1
t-PA 5 tissue-type plasminogen activator
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examined at baseline and served as a control group to the
baseline examination of the patients with hypercholesterol-
emia.
Study design. The study was approved by the ethics
committee of the University of Erlangen-Nu¨rnberg, and
performed according to the “good clinical practice” guide-
lines. Written informed consent was obtained from all
patients before study entry. After evaluation of inclusion
and exclusion criteria, possible concomitant use of lipid-
lowering drugs was discontinued in a first washout period
(day 256 to day 242). During this time period, all patients
who had not been on a stable diet for hyperlipidemia
received dietary instructions according to the “American
Heart Association Step I diet” from a registered dietitian.
The washout period was followed by a placebo run-in
period for six weeks (day 242 to day 0). Patients were finally
included according to the mean of their LDL cholesterol
concentrations measured on days 214 and 27. The follow-
ing active treatment phase (day 0 to 14) lasted 14 6 3 days.
The primary end point of the study was the assessment of
endothelium-dependent vasodilation on day 0 (baseline)
and day 14 (after treatment).
Assessment of forearm blood flow. Forearm blood flow
(FBF) and responses to different vasoactive drugs were
assessed by forearm plethysmography. Studies were per-
formed in the morning at the same time in an undisturbed
temperature-controlled environment (22 to 24°C). An
intra-arterial catheter (20 G, 8 cm, Vygon, France) was
inserted into the brachial artery of the nondominant arm
using Seldinger’s technique. After cannulation, subjects
rested for 60 min before the study was started. Subjects
lay supine with their left forearm supported above the
level of the right atrium. Forearm vascular responsiveness
to vasoactive agents was assessed by strain gauge venous-
occlusion plethysmography (EC 5R Plethysmograph,
Hokanson, Bellevue, Washington). Drugs were infused
intra-arterially at the rate of 1.5 ml/min using syringe
pumps. The following substances were administered (each
dose was infused intra-arterially for 4 min): 1) acetylcholine
(ACh) to assess endothelium-dependent vasodilation at
sequential doses of 12 and 48 mg/min; 2) sodium-
nitroprusside to test endothelium-independent vascular
relaxation (3.2 and 12.8 mg/min); and 3) simultaneous
infusion of N(G) monomethyl-L-arginine (L-NMMA) (4
mmol/min) and ACh (12 and 48 mg/min) to test whether
any improvement in endothelium-dependent vasodilatation
can be blocked by this NO synthase inhibitor. Before each
intervention, saline was infused for 15 min to let the FBF
return to resting levels. The left hand was excluded from the
circulation by the inflation of a wrist cuff to 220 mm Hg
during each measurement period. The upper arm cuff was
inflated to 40 mm Hg by a rapid cuff inflator (E20,
Hokanson, Bellevue, Washington) to occlude venous out-
flow during each measurement. Output from the strain
gauges was displayed on a monitor in real-time. A software
program coordinated the acquisition, storage and display of
data as well as inflation and deflation of the arm cuffs.
Forearm blood flow was obtained from an average of
measurements recorded for 9 s of every 15 s during the final
2 min of each infusion period.
Measurement of biochemical parameters. Lipoprotein(a)
was determined from serum by an immunonephelometric
method (Dade-Behring, Liederbach, Germany). Thrombo-
modulin was determined from EDTA-plasma by ELISA
(Pharmacia, Freiburg, Germany); tissue-type Plasmingen
activator (t-PA) and von Willebrand factor antigen were
determined from citrate plasma by ELISA (Roche, Imtec,
Mannheim, Germany). The inhibitory effect of plasmino-
gen activator inhibitor type 1 (PAI-1) on t-PA was mea-
sured by the reduction of cleavage of a chromogenic
substrate by t-PA (Dade-Behring, Liederbach, Germany).
Serum homocystein was determined by high performance
liquid chromatography.
Treatment. After the baseline evaluation, patients were
randomly assigned to one of two treatments: cerivastatin
0.4 mg or placebo once daily in the evening. Both sub-
stances were identical in appearance. Patients and treating
physicians were blinded with regard to the chosen therapy.
Statistical analysis. Differences between treatment groups
in clinical characteristics, lipid profiles, other biochemical
parameters and changes in FBF were analyzed by unpaired
and paired Student t test between before (day 0) versus after
(day 14) treatment. In addition, analysis of variance
(ANOVA) for repeated measurements was applied to test
differences in dose response curves between groups and
treatment phases. Vascular reactivity data are expressed as
blood flow in ml/min/100 ml forearm tissue (x 6 SD) and
as the percent change (x 6 SEM) from the corresponding
baseline. Biochemical parameters are expressed in absolute
values (x 6 SD) and as the percent change (x 6 SEM) from
the corresponding baseline. Linear correlation analysis
(Pearson) was used to test correlations between changes in
endothelium-dependent vasodilation and changes in lipid
profiles after therapy. Two-sided p values are given
throughout the text. A two-sided p value of , 0.05 was
considered statistically significant.
RESULTS
Changes in lipid profiles. After two weeks of lipid-lowering
therapy with cerivastatin, a decrease was found in total choles-
terol levels (286 6 54 mg/dl before therapy vs. 209 6 51 mg/dl
after therapy, p , 0.001), LDL cholesterol (198 6 48 mg/dl
vs. 132 6 47 mg/dl, p , 0.001), triglycerides (174 6
103 mg/dl vs. 109 6 47 mg/dl, p , 0.01), very low density
lipoprotein (46 6 51 mg/dl vs. 22 6 10 mg/dl, p , 0.05),
homocysteine (9.6 6 2.6 mg/dl vs. 8.7 6 2.5 mg/dl, p , 0.01),
apolipoprotein B levels (143 6 30 mg/dl vs. 106 6 29 mg/dl,
p , 0.001) and apolipoprotein E levels (5.1 6 1.5 vs. 3.4 6
0.6, p 5 0.001). High density lipoprotein (HDL) cholesterol
increased (51 6 16 mg/dl vs. 55 6 15 mg/dl, p , 0.05). There
were no significant changes in lipid profiles in the placebo
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group. Lipid profiles improved in the treatment group in
comparison with the placebo group after treatment (ANOVA)
(Table 2).
FBF responses to ACh. Baseline FBF was 4.12 6 2.34
ml/min/100 ml in the control subjects and 3.95 6 2.32
ml/min/100 ml in patients with hypercholesterolemia, re-
spectively (NS). Intra-arterial administration of ACh caused
an increase in FBF, but with diminished increases of FBF in
the patients with hypercholesterolemia for all doses of ACh
(Fig. 1). A significant correlation (r 5 20.34, p 5 0.01) was
found between LDL cholesterol serum levels and the
maximum response to ACh before therapy in the combined
group of study patients and healthy controls.
Forearm blood flow at baseline was similar in the ceriv-
astatin group and placebo group both before and after
treatment (Table 3). Intra-arterial administration of ACh
caused an increase in FBF with increasing doses in the
placebo and the treatment group, before and after therapy
(ANOVA all p , 0.001). In the cerivastatin group, how-
ever, the ACh-induced increases in FBF were enhanced
after two weeks of lipid-lowering therapy compared with
pretreatment evaluation and the placebo group (ANOVA,
p , 0.05, Fig. 2). If FBF values are given in absolute terms
for the different doses of ACh, a significant improvement of
the vasodilator response to ACh could be demonstrated
after therapy in the cerivastatin group for each single dose of
ACh (p , 0.01 and p , 0.02, respectively) (Table 3). In
contrast, we found no differences before and after therapy in
the placebo group (Table 3).
To analyze the effects in the treatment group versus
those in the placebo group, we subtracted the percent
change of FBF from baseline in response to ACh after
therapy from those before therapy. After two weeks of
treatment, cerivastatin improved the vasodilator response
compared with the placebo group significantly at dose
48 mg/min (1203 6 85% vs. 226 6 71%, p 5 0.047) with
a trend at dose 12 mg/min (1181 6 59% vs. 141 6 68%,
p 5 0.13).
Finally, in the treatment group we analyzed whether the
improvement of endothelium-dependent vasodilation after
lipid-lowering therapy was related to the degree of decreases in
LDL cholesterol, the LDL/HDL ratio or the apolipoprotein
B serum levels. No relations could be found between the
percent change of improvement of endothelium-dependent
vasodilation and the improvement of lipid profiles after therapy
(LDL cholesterol: r 5 20.30, p 5 0.09; LDL/HDL-ratio:
r 5 0.27, p 5 0.12; apolipoprotein B: r 5 20.23, p 5 0.19).
FBF responses to nitroprusside. Administration of the
endothelium-independent vasodilator sodium-nitroprusside
caused dose-dependent increases in FBF in the placebo
group before and after therapy as well as in the cerivastatin
group before and after therapy (ANOVA p , 0.001). No
differences in the observed increases after administration
of sodium-nitroprusside could be found between the
Figure 1. Impaired endothelium-dependent vasodilation in patients with
hypercholesterolemia in comparison with controls. Increase in forearm
blood flow (ml/min/100 ml) after the infusion of increasing doses of
acetylcholine in patients with hypercholesterolemia (n 5 35, solid circle)
and in healthy controls (n 5 19, solid box) (**p , 0.01, *p , 0.05).
Table 2. Comparison of Changes in Lipid Profiles After the Two Week Treatment Period








Total cholesterol (%) 226.2 6 3.5 13.3 6 3.4 0.001
LDL cholesterol (%) 233.2 6 4.1 11.8 6 4.0 0.001
HDL cholesterol (%) 16.1 6 3.8 13.2 6 3.7 NS
LDL/HDL ratio (%) 236.7 6 2.9 21.7 6 2.8 0.001
VLDL (%) 232.1 6 8.0 115.4 6 7.7 0.001
Triglycerides (%) 229.2 6 7.3 113.5 6 7.1 0.001
Apolipoprotein B (%) 226.3 6 2.4 10.6 6 2.3 0.001
Apolipoprotein E (%) 231.2 6 4.5 17.7 6 4.4 0.001
Lipoprotein (a) (%) 118.8 6 13.0 113.3 6 12.6 NS
Homocysteine (%) 28.4 6 3.1 20.8 6 3.0 NS
Thrombomodulin (%) 10.4 6 11.0 18.5 6 10.7 NS
t-PA (%) 10.7 6 13 112 6 13 NS
PAI-1 (%) 129 6 22 118 6 21 NS
vWF-antigen (%) 29.6 6 11.3 21.4 6 11.0 NS
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; PAI-1 5 plasminogen activator inhibitor type 1; t-PA 5
tissue-type plasminogen activator; VLDL 5 very low density lipoprotein; vWF antigen 5 von Willebrand factor antigen.
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cerivastatin and the placebo group both before and after
treatment, respectively (Table 3, Fig. 3).
FBF responses to ACh with simultaneous L-NMMA
infusion. Before the simultaneous intra-arterial infusion of
L-NMMA (4 mmol/min) and two increasing doses of ACh,
baseline FBF before treatment with cerivastatin was 4.62 6
2.53 ml/min/100 ml, and after treatment it was 5.08 6
2.79 ml/min/100 ml, respectively (NS). The significant
improvement in ACh-induced vasodilation after treatment
with cerivastatin (see above) was no longer observed, if
L-NMMA was coinfused (ANOVA NS). Forearm blood
flow increased from baseline at dose ACh 12 mg/min by
268 6 53% before versus 318 6 60% after treatment and
at ACh 48 mg/min by 553 6 85% before versus 505 6
86% after treatment with cerivastatin (all differences NS)
(Fig. 4).
DISCUSSION
Rapid improvement of NO availability. This study docu-
ments that lipid-lowering therapy with the HMG-CoA re-
ductase inhibitor, cerivastatin, can rapidly improve endothelial
function and the bioavailability of NO after two weeks of
therapy.
Treatment with cerivastatin improved endothelium-
dependent vasodilation in comparison with pretreatment
analysis and placebo as it has been documented for lipid-
lowering therapy in previous studies after one to 12 months
of therapy in coronary (1,2) and peripheral arteries (3,4,13).
However, the issue that improved endothelial function is
mediated by improved bioavailability of NO has been
demonstrated after only six months of therapy (4). In this
study, administration of the NO synthase inhibitor,
L-NMMA, blunted the improvement of endothelium-
dependent vasodilation after therapy. This finding indicates
Figure 2. Improved endothelium-dependent vasodilation after two weeks
of cerivastatin. Increase in forearm blood flow in percent from baseline
(D%) after the infusion of acetylcholine with increasing doses in the
cerivastatin group (n 5 17, open circle 5 before therapy, solid circle 5
after therapy) and the placebo group (n 5 18, open box 5 before therapy,
solid box 5 after therapy). Comparison of the changes between treatment
group and placebo (*p , 0.05, **p , 0.01; analysis of variance [ANOVA]
p , 0.05).
Figure 3. Unaffected endothelium-independent vasodilation after two
weeks of cerivastatin. Increase in forearm blood flow in percent from
baseline (D%) after the infusion of nitroprusside with increasing doses in
the cerivastatin group (n 5 17, open circle 5 before therapy, solid
circle 5 after therapy) and the placebo group (n 5 18, open box 5 before
therapy, solid box 5 after therapy). Comparison of the changes between
the treatment group and placebo (all NS).
Table 3. Forearm Blood Flow (ml/min/100 ml) at Baseline and Changes From Baseline for Different Doses of Intra-Arterial ACh
and Sodium Nitroprusside in the Cerivastatin and the Placebo Group (x 6 SD)
Change
(ml/min/100 ml)
Cerivastatin (n 5 17)
p Value
Placebo (n 5 18)
p Value
Before After Before After
Therapy Therapy
Ach
Baseline 4.19 6 2.43 4.38 6 2.71 NS 3.71 6 1.29 3.97 6 1.83 NS
12 mg/min 111.2 6 7.88 122.3 6 21.3 0.01 19.00 6 8.04 112.9 6 15.3 NS
48 mg/min 119.1 6 12.7 131.2 6 26.1 0.02 119.4 6 12.7 120.7 6 15.8 NS
Nitroprusside
Baseline 5.35 6 3.22 5.84 6 4.31 NS 5.05 6 1.85 5.74 6 2.81 NS
3.2 mg/min 112.6 6 7.04 116.2 6 10.4 NS 110.5 6 5.28 111.5 6 4.56 NS
12.8 mg/min 124.3 6 11.4 125.6 6 9.43 NS 122.7 6 12.9 122.0 6 12.8 NS
Corresponding p values for comparison before and after the treatment period (Student t test).
ACh 5 acetylcholine.
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that a rapidly increased bioavailability of NO mediates
improved endothelium-dependent vasodilation found after
two weeks. To our knowledge, this is the shortest time
period demonstrated for HMG-CoA reductase inhibitors
to improve NO bioavailability. For LDL apheresis, im-
proved endothelium-dependent vasodilation has been sug-
gested after a single LDL apheresis (15,16). However, in
these studies, endothelial function may have been affected
not only by reduction of LDL cholesterol but also by the
administration of heparin during apheresis. Heparin has
recently been shown to affect the vascular endothelium by
activating endothelium NO synthase and the NO-cGMP
pathway leading to improved endothelium-dependent vaso-
dilation (18,19).
Thrombostatic parameters. It was previously suggested
that lipid-lowering therapy could improve thrombostatic
parameters that may serve as endothelial cell markers in
patients with hypercholesterolemia (20). In our study,
PAI-1, t-PA, von Willebrand factor and thrombomodulin
were not elevated in patients with hypercholesterolemia
with impaired endothelial function. Thus, not surprisingly,
no treatment effect could be detected on these parameters
after lipid-lowering therapy.
Potential mechanisms. In patients with hypercholesterol-
emia, the bioavailability of NO is impaired either through
decreased synthesis of NO or, even more importantly,
through increased breakdown of NO (21). It has been
suggested that hypercholesterolemia stimulates the genera-
tion of superoxide radicals by the endothelial NO synthase
itself or through stimulation of different oxidases, such as
NAD(P)H-dependent oxidases, which are influenced by the
renin-angiotensin system (22,23). Superoxide directly inac-
tivates NO and may also increase the subsequent oxidation
of LDL particles by the formation of the powerful oxidant,
peroxynitrite (21). A reduction in serum cholesterol is
associated with the normalization of oxygen-derived free
radical production (24). In this study, LDL cholesterol
decreased by 33% after two weeks and was accompanied by
a decrease in LDL/HDL ratio, triglycerides, very low
density lipoprotein and apolipoprotein B and E. Thus,
decrease of free radical production and consecutively less
degradation of NO could explain the observed improvement
in the bioavailability of NO and, thus, in endothelium-
dependent vasodilation in our patients.
Although LDL cholesterol and superoxide production in
particular are clearly associated with endothelial dysfunction
and reduced bioavailability of NO, therapy with statins may
improve endothelial function through other mechanisms
independent of their lipid-lowering effects. In this context,
statins have been demonstrated to activate endothelial NO
synthase, independent of their cholesterol-lowering actions
(25) and to decrease superoxide formation (26) by decreas-
ing inducible NO synthase induction (27) and decreasing
NAD(P)H oxidase activity. The latter effect is probably
related to a statin-dependent down-regulation of angioten-
sin II type 1 receptor expression on smooth muscle cells,
which has been demonstrated to be up-regulated in hyper-
cholesterolemia and to stimulate NAD(P)H oxidase-
dependent superoxide formation (22,28). Thus, indepen-
dent of their lipid-lowering actions, statins may improve
endothelial function by a further increase of NO synthesis
and decrease of oxidative stress. The improvement of
endothelium-dependent vasodilation found in our study was
not clearly related to the reduction in LDL cholesterol or
other lipid fractions. Although our study was clearly not
designed to investigate such lipid-independent effects of
statin therapy, we consequently cannot exclude that, in
addition to the improved lipid profiles, other effects may
have contributed to the improvement of endothelium-
dependent vasodilation.
Possible clinical implications. Despite the well-
recognized efficacy of lipid-lowering therapy in the second-
ary prevention of coronary syndromes, treatment of hyper-
cholesterolemia is usually delayed during the acute phase of
coronary syndromes (17). Concern with the validity of
elevated in-hospital cholesterol values and the lack of-
demonstrated short-term benefits of lipid-lowering therapy
may explain this delay in therapy. Lipid-lowering therapy is
often started only after hospital discharge by the patient’s
general practitioner.
Figure 4. Improved endothelium-dependent vasodilation after cerivastatin
therapy can be blocked with L-NMMA. Changes in forearm blood flow in
percent from baseline (D%) after the infusion of acetylcholine (ACh) 12
mg/min (ACh 12, upper panel) and 48 mg/min (ACh 48, lower panel)
without (left two columns) and with (right two columns) coinfusion of
the nitric oxide synthase inhibitor L-NMMA 4 mmol/min before (open
box) and after (solid box) lipid-lowering therapy with cerivastatin for two
weeks. L-NMMA 5 N(G)-monomethyl-L-arginine.
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In this study, we have shown that lipid profile improve-
ment can be achieved rapidly within two weeks. Cerivastatin
effectively reduced total cholesterol, LDL cholesterol, very
low density lipoprotein and triglycerides and increased
HDL cholesterol after this short period. These improved
lipid profiles were accompanied by improved bioavailability
of NO, an effect that is highly desirable during the acute
phase of coronary syndromes. Thus, our data support the
concept that lipid-lowering therapy with statins may play a
role, not only for prevention, but for therapy of acute
coronary syndromes.
However, in this study only patients with hypercholes-
terolemia but without overt atherosclerosis or even coronary
events, were investigated. The very recently published Cor-
onary Artery Reactivity After Treatment with Simvastatin
(CARATS) study in patients with mild-to-moderate coro-
nary artery disease did not reveal any benefits of therapy
with simvastatin on endothelial function after six months
of therapy (29). However, in this study the average baseline
LDL cholesterol was lower (average LDL cholesterol
130 mg/dl) than it was in participants in previous studies
that showed improvement in coronary endothelial vasodi-
lator function with statin therapy (1,2). Recently, the
REduction of Cholesterol in Ischemia and Function of the
Endothelium (RECIFE) trial demonstrated an improved
endothelial function in patients with acute coronary syn-
dromes after six weeks of therapy with pravastatin (14). In
this trial endothelial function was measured as flow-
mediated dilation of the brachial artery by ultrasound, a
method that does not specifically assess the NO-cGMP
pathway. Our data obtained by intra-arterial administration
of vasoactive substances affecting the NO-cGMP pathway
provide evidence of rapidly achieved benefits of lipid-
lowering therapy. Further trials are required to determine
whether this rapid improvement of the bioavailability of
NO can be achieved in patients with acute coronary syn-
dromes in the early recovery phase and whether this is
associated with a reduction of cardiovascular events and
improved outcome.
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